

New Drug Manufacturer Report

| Section | Data element | Field type | Drug #1 |
|----------------------------|--|------------|--|
| 1. Drug identification | National drug code (11-digit NDC) | Numeric | 00527-2133-35 |
| | Drug name | Text | POSACONAZOLE 100 mg |
| 2. Drug Launch Information | Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally | Text | Lannett sets a single, transparent price per product, regardless of the volume purchased. Lannett sets its POSACONAZOLE 100 mg prices at approximately cost plus a margin to cover Lannett's overhead and research and development expenses. |
| | Estimated volume of patients who may be prescribed the drug | Numeric | 25.36 |
| | Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval | Text | Not breakthrough therapy or Priority Review |
| | Date and price of acquisition if the drug was not developed by the manufacturer | Text | N/A - product not acquired |